AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.
The Cambridge-based pharmaceutical company said that the latest analysis of the trial revealed Imfinzi combined with platinum-based chemotherapy, followed by Imfinzi plus Lynparza, demonstrated an improvement in multiple key areas for patients compared to chemotherapy alone.
The trial, which involved 699 patients, found that the risk of second progression or death for patients treated with Lynparza and Imfinzi reduced by 32% versus the control arm.
‘Duo-E results have shown that adding Imfinzi to chemotherapy delivers better outcomes for patients with advanced endometrial cancer. In addition, to achieve optimal clinical benefit for patients with the greatest unmet need – those with mismatch repair proficient disease – the addition of Lynparza further enhances the effect of checkpoint inhibition in endometrial cancer,’ said Susan Galbraith, executive vice president of oncology R&D at AstraZeneca.
Shares in AstraZeneca were down 0.3% to 10,266.00 pence in London on Monday afternoon.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
